Results 1 to 10 of about 1,349 (69)

Randomized interventional clinical trial to estimate the efficacy of clomiphene citrate versus letrozole in induction of ovulation in infertility [PDF]

open access: yesNew Indian Journal of OBGYN, 2022
Background and objectives: Anovulation accounts for 30-40% of female infertility. The treatment of choice is by ovulation induction. This study is to estimate effectiveness of clomiphene citrate versus letrozole in ovulation induction.
Yogindra Kumar Manohar Kabadi   +1 more
doaj   +1 more source

Maternal aromatase inhibition via letrozole altered RFamide-related peptide-3 and gonadotropin-releasing hormone expression in pubertal female rats [PDF]

open access: yesIranian Journal of Basic Medical Sciences, 2022
Objective(s): Despite prevalence of polycystic ovary syndrome (PCOS) among childbearing women and development of many animal models for this syndrome, information on its etiology is still scarce.
Zahra Shaaban   +4 more
doaj   +1 more source

Poloxamer188 composite electrospun poly L-lactic acid fibrous nonwoven: Sustained and release letrozole as a subcutaneous implant

open access: yesJournal of Industrial Textiles, 2022
Poloxamer188 composite poly L-lactic acid (PLLA) electrospun fibrous nonwovens (EFNW) were prepared by simple letrozole-poloxamer188-PLLA co-solution electrospinning and used as subcutaneous implants to sustained release letrozole.
Hao Wang   +5 more
doaj   +1 more source

Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis

open access: yesFrontiers in Oncology, 2022
BackgroundCyclin-dependent kinase 4/6 inhibitors are a standard treatment for patients with hormone receptor−positive (HR+)/human epidermal growth factor receptor 2−negative (HER2−) metastatic breast cancer (MBC).
Adam Brufsky   +4 more
doaj   +1 more source

Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer

open access: yesBreast, 2023
Background: Palbociclib, the first available cyclin-dependent kinase 4/6 inhibitor, plus endocrine therapy is approved for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (MBC).
Hope S. Rugo   +5 more
doaj   +1 more source

Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model

open access: yesHealth Economics Review, 2023
Background Palbociclib and Ribociclib are cyclin-dependent kinase 4/6 oral molecular inhibitors that have the potential to improve overall survival (OS), progression-free survival (PFS), and quality of life in patients with metastatic breast cancer (MBC).
Ali Darvishi   +2 more
doaj   +1 more source

Effects of letrozole co-treatment on the cumulative live-birth rate among normal responders in gonadotropin-releasing hormone antagonist cycles

open access: yesFrontiers in Medicine, 2022
Studies have shown that letrozole cotreatment can improve clinical outcomes in high and poor responders in GnRH-antagonist protocol. However, whether letrozole is also beneficial to normal responders is not known.
Shuyi Zhang   +5 more
doaj   +1 more source

Effect of Letrozole versus Clomiphene Citrate on Endometrial Receptivity and Peri follicular Vascularity in Infertile Women with Polycystic Ovarian Syndrome [PDF]

open access: yesZagazig University Medical Journal, 2023
Background: Polycystic ovarian syndrome is the most common endocrine problem in females with an incidence of (6 -10%) . The purpose of this study was to make acomparison between the effect of clomiphene citrate versus letrozole on the endometrial ...
ASMAA ELOSS   +3 more
doaj   +1 more source

Comparative study between the effect of letrozole versus letrozole with Metformin in treatment of anovulation in overweight women. [PDF]

open access: yesAl-Azhar International Medical Journal, 2022
Background: Ovulation disorders account for around 30% of infertility and are frequently accompanied by irregular menstrual (oligomenorrhoea) or an absence of periods (amenorrhea).
Samir Galal   +2 more
doaj   +1 more source

Letrozole 2.5 mg Shows Higher Endometrial Thickness Compared to 5 mg Letrozole in Ovulation Induction

open access: yesIndonesian Journal of Obstetrics and Gynecology, 2012
Objective: To compare the effects of ovulation induction with 2.5 mg letrozole to 5 mg letrozole by the number of mature follicles, endometrial morphology and endometrium thickness during the late follicular phase in infertility patient who successfully ...
Anita Tobing
doaj   +1 more source

Home - About - Disclaimer - Privacy